In Advanced Prostate Cancer, a String of Modest Gains Are Changing Patient Care

Robert Dreicer, MD, MS, MACP, FASCO, acknowledges that there have been substantial developments in therapies and strategies for treating prostate cancer, leading to heightened expectations of breakthroughs in the field.

Related Keywords

United States ,Utah ,Salt Lake City ,Neeraj Agarwal ,Robert Dreicer ,Utah Huntsman Cancer Institute Center ,Drug Administration ,University Of Virginia School Medicine ,Investigational Therapeutics Genitourinary Oncology Program ,University Of Utah Huntsman Cancer Institute ,Virginia School ,Lake City ,Huntsman Cancer Institute ,Investigational Therapeutics ,Genitourinary Oncology Program ,Accessed July ,Plus Abiraterone ,Adult Patients With ,Cancer Prostatic ,News ,Articles ,Special Report ,Prostate Cancer ,Parp Inhibition ,D ,Pasco ,Talapro 2 ,Nct095197 ,Hrr Gene ,Xtandi ,Enzalutimide ,Androgen Deprivation Therapy ,Adt ,Zytiga ,Abiraterone Acetate ,Apalutamide ,Erleada ,Darolutamide ,Nubeqa ,